These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
408 related articles for article (PubMed ID: 21902666)
1. Role of sirtuins and calorie restriction in neuroprotection: implications in Alzheimer's and Parkinson's diseases. Srivastava S; Haigis MC Curr Pharm Des; 2011; 17(31):3418-33. PubMed ID: 21902666 [TBL] [Abstract][Full Text] [Related]
2. Multifaced role of protein deacetylase sirtuins in neurodegenerative disease. Gupta R; Ambasta RK; Kumar P Neurosci Biobehav Rev; 2022 Jan; 132():976-997. PubMed ID: 34742724 [TBL] [Abstract][Full Text] [Related]
7. Sirtuins and Their Implications in Neurodegenerative Diseases from a Drug Discovery Perspective. Yeong KY; Berdigaliyev N; Chang Y ACS Chem Neurosci; 2020 Dec; 11(24):4073-4091. PubMed ID: 33280374 [TBL] [Abstract][Full Text] [Related]
8. Iron neurochemistry in Alzheimer's disease and Parkinson's disease: targets for therapeutics. Belaidi AA; Bush AI J Neurochem; 2016 Oct; 139 Suppl 1():179-197. PubMed ID: 26545340 [TBL] [Abstract][Full Text] [Related]
9. Effects of caloric restriction on cardiac oxidative stress and mitochondrial bioenergetics: potential role of cardiac sirtuins. Shinmura K Oxid Med Cell Longev; 2013; 2013():528935. PubMed ID: 23577224 [TBL] [Abstract][Full Text] [Related]
11. Modulation of sirtuins: new targets for antiageing. Pallàs M; Verdaguer E; Tajes M; Gutierrez-Cuesta J; Camins A Recent Pat CNS Drug Discov; 2008 Jan; 3(1):61-9. PubMed ID: 18221243 [TBL] [Abstract][Full Text] [Related]
12. Cellular and molecular mechanisms underlying perturbed energy metabolism and neuronal degeneration in Alzheimer's and Parkinson's diseases. Mattson MP; Pedersen WA; Duan W; Culmsee C; Camandola S Ann N Y Acad Sci; 1999; 893():154-75. PubMed ID: 10672236 [TBL] [Abstract][Full Text] [Related]
13. Sirtuins as novel targets for Alzheimer's disease and other neurodegenerative disorders: experimental and genetic evidence. Albani D; Polito L; Forloni G J Alzheimers Dis; 2010; 19(1):11-26. PubMed ID: 20061622 [TBL] [Abstract][Full Text] [Related]
14. Potential therapeutic targets for neurodegenerative diseases: lessons learned from calorie restriction. Duan W; Ross CA Curr Drug Targets; 2010 Oct; 11(10):1281-92. PubMed ID: 20840070 [TBL] [Abstract][Full Text] [Related]
15. After the grape rush: sirtuins as epigenetic drug targets in neurodegenerative disorders. Huber K; Superti-Furga G Bioorg Med Chem; 2011 Jun; 19(12):3616-24. PubMed ID: 21306906 [TBL] [Abstract][Full Text] [Related]
16. Aldehyde dehydrogenase 2 in the spotlight: The link between mitochondria and neurodegeneration. Deza-Ponzio R; Herrera ML; Bellini MJ; Virgolini MB; Hereñú CB Neurotoxicology; 2018 Sep; 68():19-24. PubMed ID: 29936317 [TBL] [Abstract][Full Text] [Related]
17. The sirtuins, oxidative stress and aging: an emerging link. Merksamer PI; Liu Y; He W; Hirschey MD; Chen D; Verdin E Aging (Albany NY); 2013 Mar; 5(3):144-50. PubMed ID: 23474711 [TBL] [Abstract][Full Text] [Related]
18. Mitochondrial Sirtuins in Parkinson's Disease. He L; Wang J; Yang Y; Li J; Tu H Neurochem Res; 2022 Jun; 47(6):1491-1502. PubMed ID: 35220492 [TBL] [Abstract][Full Text] [Related]
19. Sirtuin deacetylases in neurodegenerative diseases of aging. Herskovits AZ; Guarente L Cell Res; 2013 Jun; 23(6):746-58. PubMed ID: 23689277 [TBL] [Abstract][Full Text] [Related]
20. Therapeutic potential of sirtuin-activating compounds in Alzheimer's disease. Gan L Drug News Perspect; 2007 May; 20(4):233-9. PubMed ID: 17637936 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]